BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30013779)

  • 1. Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of
    Mori N; Nishiura Y; Suga D; Moritani I; Yamanaka Y; Ooya Y; Inoue H; Takase K; Hioki M; Shiraki K
    Biomed Rep; 2018 Aug; 9(2):169-174. PubMed ID: 30013779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant
    Sue S; Suzuki Y; Sasaki T; Kaneko H; Irie K; Komatsu K; Maeda S
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
    Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.
    Saito Y; Konno K; Sato M; Nakano M; Kato Y; Saito H; Serizawa H
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
    Nishida T; Tsujii Y; Okamoto A; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Nakamatsu D; Matsubara T; Hayashi S; Yamamoto M; Nakajima S; Fukui K; Inada M
    Digestion; 2020; 101(5):608-614. PubMed ID: 31288235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
    Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
    Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Vonoprazan in
    Sugimoto M; Yamaoka Y
    Front Pharmacol; 2018; 9():1560. PubMed ID: 30697158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
    Sue S; Maeda S
    Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of
    Hojo M; Asaoka D; Takeda T; Shimada Y; Matsumoto K; Matsumoto K; Yatagai N; Akazawa Y; Ueda K; Ueyama H; Nagahara A
    Therap Adv Gastroenterol; 2020; 13():1756284820966247. PubMed ID: 33240391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
    Asaka M; Sugiyama T; Kato M; Satoh K; Kuwayama H; Fukuda Y; Fujioka T; Takemoto T; Kimura K; Shimoyama T; Shimizu K; Kobayashi S
    Helicobacter; 2001 Sep; 6(3):254-61. PubMed ID: 11683930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
    Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
    Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
    [No Abstract]   [Full Text] [Related]  

  • 13. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ; Singh TP; Wei X; Yao H; Wang HL
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of
    Lin Y; Xu H; Yun J; Yu X; Shi Y; Zhang D
    Ann Transl Med; 2022 Sep; 10(18):987. PubMed ID: 36267745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
    Asaoka D; Nagahara A; Matsuhisa T; Takahashi S; Tokunaga K; Kawai T; Kawakami K; Suzuki H; Suzuki M; Nishizawa T; Kurihara N; Ito M; Sasaki H; Omata F; Mizuno S; Torii A; Ohkusa T; Mine T; Sakaki N
    Helicobacter; 2013 Dec; 18(6):468-72. PubMed ID: 23773231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
    Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of
    Zhang Z; Liu F; Ai F; Chen X; Liu R; Zhang C; Fang N; Fu T; Wang X; Tang A
    Front Pharmacol; 2023; 14():1143969. PubMed ID: 37214450
    [No Abstract]   [Full Text] [Related]  

  • 19. First-Line
    Sue S; Suzuki N; Shibata W; Sasaki T; Yamada H; Kaneko H; Tamura T; Ishii T; Kondo M; Maeda S
    Gastroenterol Res Pract; 2017; 2017():2019802. PubMed ID: 29181022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and effectiveness of vonoprazan-based
    Ashida K; Honda Y; Sanada K; Takemura Y; Sakamoto S
    Expert Opin Drug Saf; 2019 Dec; 18(12):1255-1261. PubMed ID: 31646920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.